Resveratrol for Type 2 Diabetes

Verdict: Disputed and weak; not a reliable treatment

The evidence that resveratrol controls type 2 diabetes is weak and genuinely conflicting: the most rigorous reviews and the largest trial found no benefit, while smaller meta-analyses report only modest effects that depend on doses far above what regulators allow. It should not replace proven diabetes care.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

This earns a weak, disputed grade because the strongest evidence points against a real benefit. A Cochrane review (PMID 31978258) found no effect on HbA1c, fasting glucose or HOMA-IR; an umbrella review of meta-analyses (PMID 34320173) concluded the data do not support resveratrol for cardiometabolic management in type 2 diabetes; and the largest, longest trial (PMID 27520400, 192 patients over six months) showed nothing at either 40 or 500 mg per day.

Several moderate-quality meta-analyses do report reductions in HbA1c, HOMA-IR and fasting glucose (PMID 33480264, PMID 34484395, PMID 35685602). But these effects are small, inconsistent across studies, and largely confined to short trials using high doses of 1000 mg per day or more. That level sits far above the 150 mg per day ceiling set by EU and Taiwan regulators, so any benefit is hard to obtain legally or in practice.

Authorities reinforce the caution. The US FDA has authorized no health claim and ceased evaluating resveratrol at the notifier's request, EFSA permits it only as a capped novel food with no approved claims, Harvard Health reports no proven human benefit, and the American Diabetes Association recommends against supplements of this kind. There is also a real interaction risk in diabetics, including with warfarin and oral hypoglycemics, so diet, weight loss, exercise and standard medication remain the established options.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.41
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
72%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.25
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.41
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Resveratrol in type 2 diabetes, metabolic syndrome, NAFLD: umbrella review of meta-analyses of RCTs
PMID: 34320173 2021 系統性回顧 n = 1,476
Finding: Short-term HbA1c reduction MD -1.05% (95% CI -2.09 to -0.02); most other outcomes trivial with very low-to-low certainty evidence; overall does NOT support resveratrol for cardiometabolic management in T2D.
🟢 High quality Effect size: HbA1c MD -1.05% (short-term only)
View on PubMed
Resveratrol for adults with type 2 diabetes mellitus (Cochrane review)
PMID: 31978258 2020 系統性回顧 n = 50
Finding: HbA1c MD +0.1% (p=0.09), fasting glucose MD +2 mg/dL (p=0.29), HOMA-IR MD -0.35 (p=0.27) — all neutral vs placebo; insufficient evidence to evaluate efficacy.
🟢 High quality Government Effect size: null (all non-significant)
View on PubMed
Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis
PMID: 33480264 2022 統合分析
Finding: Significant reductions in HbA1c (SMD -0.64; p=0.01), HOMA-IR (SMD -0.34; p=0.01), and fasting glucose in diabetic subgroup (SMD -0.85; p=0.01); ~60% of included studies showed at least one significant effect.
Effect size: HbA1c SMD -0.64; HOMA-IR SMD -0.34; FBG SMD -0.85 (diabetics only)
View on PubMed
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis
PMID: 35685602 2022 統合分析 n = 1,151
Finding: High-dose (≥1000 mg) reduced fasting glucose by 18.76 mg/dL (95% CI -23.43 to -14.09; p<0.00001); systolic BP -7.97 mmHg; no effect on waist circumference, triglycerides, or HDL.
Effect size: FBG MD -18.76 mg/dL (high-dose only); SBP MD -7.97 mmHg
View on PubMed
Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose in Type 2 Diabetes: SR and Meta-Analysis of RCTs
PMID: 34484395 2021 統合分析 n = 896
Finding: HOMA-IR significantly reduced (WMD -0.99; 95% CI -1.61 to -0.38; p=0.002); no significant effect on total cholesterol (p=0.13) or triglycerides (p=0.21); fasting glucose and insulin improved.
Effect size: HOMA-IR WMD -0.99
View on PubMed
Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial
PMID: 27520400 2016 RCT (double-blind) n = 192
Finding: No significant differences in glucose, HbA1c, insulin, blood pressure, or lipids vs placebo at either dose after 6 months (all p=NS).
🟢 High quality Effect size: null (all non-significant)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
At the notifier's request, FDA ceased to evaluate this notice source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Neutral
訂定「以基因改造啤酒酵母(Saccharomyces cerevisiae) EFSC4687菌株發酵生產之食品原料反式白藜蘆醇(trans-resveratrol)之使用限制及標示規定」,並自即日生效。限用於供成人使用之膳食補充品,每日攝取量上限為150毫克。本產品限供成人使用,孕婦及授乳者應避免食用;服用藥物者須諮詢醫師方可使用。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-resveratrol-001 繁體中文版 →